PharmaCyte Biotech Inc Strategic Asset Allocation Index
PharmaCyte Biotech Inc strategic asset allocation index. PharmaCyte Biotech Inc (PMCB) has a Strategic Asset Allocation Index of 0.0% as of April 2026. Strategic assets (PP&E of $- plus long-term investments of $0.00) total $0.00, measured against net assets of $34.98 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See PharmaCyte Biotech Inc net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of PharmaCyte Biotech Inc (2006–2026)
Strategic asset allocation index of PharmaCyte Biotech Inc from 2006 to 2026. This chart shows how PharmaCyte Biotech Inc's Strategic Asset Allocation Index has evolved across 17 annual periods from 2006 to 2026. As of April 2026, the index stands at 0.0%, representing strategic assets of $0.00 against net assets of $34.98 Million USD. Check PharmaCyte Biotech Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.
PharmaCyte Biotech Inc Strategic Asset Allocation Index by Year (2006–2026)
PharmaCyte Biotech Inc strategic asset allocation index by year from 2006 to 2026. The table below presents the year-by-year Strategic Asset Allocation Index for PharmaCyte Biotech Inc from 2006 to 2026, covering 17 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see PMCB market cap.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2026 | 0.0% | $0.00 | $- | $0.00 | $34.98 Million | ▼ -43.3 pp |
| 2025 | 43.3% | $22.47 Million | $- | $22.47 Million | $51.89 Million | ▲ +43.3 pp |
| 2024 | 0.0% | $0.00 | $- | $0.00 | $39.51 Million | ▼ -2.2 pp |
| 2023 | 2.2% | $1.57 Million | $- | $1.57 Million | $72.69 Million | ▲ +0.4 pp |
| 2022 | 1.7% | $1.57 Million | $- | $1.57 Million | $89.92 Million | ▼ -21.8 pp |
| 2021 | 23.5% | $1.57 Million | $- | $1.57 Million | $6.68 Million | ▼ -7.4 pp |
| 2020 | 30.9% | $1.57 Million | $- | $1.57 Million | $5.09 Million | ▼ -0.3 pp |
| 2019 | 31.2% | $1.57 Million | $- | $1.57 Million | $5.04 Million | ▲ +3.9 pp |
| 2018 | 27.3% | $1.57 Million | $- | $1.57 Million | $5.77 Million | ▲ +7.8 pp |
| 2017 | 19.4% | $1.57 Million | $- | $1.57 Million | $8.09 Million | ▼ -4.7 pp |
| 2016 | 24.1% | $1.57 Million | $- | $1.57 Million | $6.52 Million | ▼ -2.4 pp |
| 2015 | 26.5% | $1.57 Million | $- | $1.57 Million | $5.94 Million | ▲ +8.9 pp |
| 2014 | 17.6% | $1.57 Million | $- | $1.57 Million | $8.94 Million | ▼ -67.1 pp |
| 2009 | 84.7% | $2.64 Million | $2.64 Million | $- | $3.12 Million | ▲ +84.3 pp |
| 2008 | 0.3% | $23.00K | $23.00K | $- | $7.44 Million | ▲ +0.1 pp |
| 2007 | 0.2% | $8.00K | $8.00K | $- | $4.29 Million | ▲ +0.0 pp |
| 2006 | 0.2% | $7.00K | $7.00K | $- | $4.41 Million | — |